News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,753 Results
Type
Article (39693)
Company Profile (247)
Press Release (658813)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204164)
Career Advice (2007)
Deals (35420)
Drug Delivery (95)
Drug Development (81049)
Employer Resources (172)
FDA (16180)
Job Trends (14857)
News (345190)
Policy (32540)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49433)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (252)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2252)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (150)
Cell therapy (421)
Cervical cancer (19)
Clinical research (65983)
Collaboration (832)
Compensation (529)
Complete response letters (19)
COVID-19 (2589)
CRISPR (40)
C-suite (240)
Cystic fibrosis (100)
Data (2197)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (270)
Diagnostics (6368)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86610)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112376)
Executive appointments (722)
FDA (17432)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (707)
Government (4415)
Grass and pollen (4)
Guidances (62)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2731)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16510)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (66)
Medical device (13375)
Medtech (13380)
Mergers & acquisitions (19453)
Metabolic disorders (682)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1910)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (86)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57291)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20553)
Phase II (29057)
Phase III (21649)
Pipeline (1191)
Policy (138)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22280)
Reports (46)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (685)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (168)
Last 7 days (863)
Last 30 days (2640)
Last 365 days (32847)
2025 (10628)
2024 (35218)
2023 (40076)
2022 (51177)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35023)
2017 (32114)
2016 (31483)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28571)
2011 (29266)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37855)
Australia (6184)
California (6110)
Canada (2008)
China (521)
Colorado (265)
Connecticut (274)
Delaware (146)
Europe (81231)
Florida (908)
Georgia (206)
Idaho (57)
Illinois (534)
India (25)
Indiana (306)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (889)
Massachusetts (4555)
Michigan (220)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1723)
New Mexico (28)
New York (1738)
North Carolina (964)
North Dakota (8)
Northern California (2673)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1373)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2292)
Tennessee (101)
Texas (904)
United States (23045)
Utah (180)
Virginia (144)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
698,753 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025
March 20, 2025
·
1 min read
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. announces the strategic decisions on farnesoid X receptor agonist ASC42.
April 3, 2024
·
2 min read
Press Releases
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
April 23, 2025
·
5 min read
Press Releases
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
April 1, 2025
·
4 min read
Press Releases
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide
March 12, 2025
·
6 min read
Press Releases
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
February 19, 2025
·
4 min read
Press Releases
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
November 12, 2024
·
2 min read
Press Releases
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
January 21, 2025
·
6 min read
Drug Development
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
January 24, 2024
·
2 min read
Drug Development
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. announces initiation of the Phase III clinical trial of fatty acid synthase inhibitor ASC40 for treatment of moderate to severe acne vulgaris.
December 5, 2023
·
4 min read
1 of 69,876
Next
